$385 Million is the total value of Avoro Capital Advisors LLC's 36 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 64.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Sell | AMICUS THERAPEUTICS INC | $59,460,000 | -8.5% | 4,250,199 | -7.4% | 15.46% | -13.6% |
| MRTX | Buy | MIRATI THERAPEUTICS INC. | $50,014,000 | +58.9% | 1,453,055 | +45.3% | 13.00% | +50.0% |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $23,965,000 | +31.3% | 2,124,593 | +47.7% | 6.23% | +23.9% |
| Buy | NEURODERM LTD. | $22,801,000 | +300.2% | 1,103,093 | +197.2% | 5.93% | +277.8% | |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO. | $22,351,000 | +49.0% | 804,299 | +31.4% | 5.81% | +40.7% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $19,243,000 | -7.2% | 581,900 | +17.6% | 5.00% | -12.4% |
| PTX | Buy | PERNIX THERAPEUTICS HOLDINGS | $18,974,000 | +156.4% | 6,004,564 | +380.3% | 4.93% | +142.1% |
| LBIO | Buy | LION BIOTECHNOLOGIES INC | $18,322,000 | -31.6% | 3,180,913 | +8.8% | 4.76% | -35.5% |
| SRNE | Sell | SORRENTO THERAPEUTICS INC | $18,051,000 | -53.1% | 2,151,437 | -1.6% | 4.69% | -55.8% |
| ONTY | Sell | ONCOTHYREON INC | $15,088,000 | -28.2% | 5,506,618 | -2.0% | 3.92% | -32.2% |
| SRPT | New | SAREPTA THERAPEUTICS -INC | $15,060,000 | – | 469,025 | +100.0% | 3.92% | – |
| IG | Buy | IGI LABORATORIES INC | $11,640,000 | +5.4% | 1,779,782 | +1.5% | 3.03% | -0.6% |
| AEGR | New | AEGERION PHARMACEUTICALS INC | $10,966,000 | – | 806,300 | +100.0% | 2.85% | – |
| AGEN | AGENUS - INC | $10,116,000 | -46.7% | 2,199,137 | 0.0% | 2.63% | -49.7% | |
| DERM | New | DERMIRA INC | $8,478,000 | – | 363,250 | +100.0% | 2.20% | – |
| SPPI | New | SPECTRUM PHARMACEUTICALS INC | $7,867,000 | – | 1,315,600 | +100.0% | 2.04% | – |
| NK | New | NANTKWEST- INC | $7,301,000 | – | 728,887 | +100.0% | 1.90% | – |
| INNL | Buy | INNOCOLL AGsponsored adr | $6,290,000 | -13.6% | 502,422 | +1.0% | 1.64% | -18.4% |
| EGLTQ | New | EGALET CORPORATION. | $5,807,000 | – | 440,606 | +100.0% | 1.51% | – |
| AXGT | Buy | AXOVANT SCIENCES LTD. | $5,252,000 | -24.2% | 406,470 | +19.6% | 1.36% | -28.5% |
| IWM | New | ISHARES RUSSELL 2000 ETFput | $4,979,000 | – | 1,280,000 | +100.0% | 1.29% | – |
| VCYT | Buy | VERACYTE INC | $3,622,000 | -57.1% | 772,297 | +1.8% | 0.94% | -59.5% |
| Buy | TRILLIUM THERAPEUTICS INC | $3,351,000 | +62.7% | 255,097 | +170.2% | 0.87% | +53.6% | |
| FBIO | Buy | FORTRESS BIOTECH INC. | $3,316,000 | +6.2% | 1,275,521 | +37.2% | 0.86% | +0.2% |
| VCEL | Buy | VERICEL CORP. | $3,076,000 | -20.5% | 1,135,120 | +4.8% | 0.80% | -24.9% |
| ALQA | Buy | ALLIQUA BIOMEDICAL INC | $2,695,000 | -36.1% | 850,000 | +6.2% | 0.70% | -39.6% |
| TNXP | Sell | TONIX PHARMACEUTICALS HLDG | $2,170,000 | -68.0% | 410,300 | -45.7% | 0.56% | -69.8% |
| HTBX | Buy | HEAT BIOLOGICS INC | $1,576,000 | -21.6% | 341,064 | +1.8% | 0.41% | -26.0% |
| SRPT | New | SAREPTA THERAPEUTICS -INCcall | $1,237,000 | – | 178,300 | +100.0% | 0.32% | – |
| CLLS | Buy | CELLECTIS - ADRsponsored ads | $923,000 | -14.7% | 35,000 | +16.7% | 0.24% | -19.5% |
| CBIO | New | CATALYST BIOSCIENCES INC. | $391,000 | – | 83,901 | +100.0% | 0.10% | – |
| HRTX | New | HERON THERAPEUTICS INCcall | $153,000 | – | 500,000 | +100.0% | 0.04% | – |
| KITE | New | KITE PHARMA INC.put | $113,000 | – | 26,000 | +100.0% | 0.03% | – |
| Exit | SPDR SERIES TRUST - S&P BIOTECHput | $0 | – | -350,000 | -100.0% | -0.21% | – | |
| TRGT | Exit | TARGACEPT INC | $0 | – | -587,315 | -100.0% | -0.45% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -4,500 | -100.0% | -0.50% | – |
| ADAP | Exit | ADAPTIMMUNE THERAPEUTICS-ADRsponsored adr | $0 | – | -183,900 | -100.0% | -0.93% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -1.29% | – |
| RCPT | Exit | RECEPTOS INC | $0 | – | -26,500 | -100.0% | -1.39% | – |
| BLCM | Exit | BELLICUM PHARMACEUTICALS INC | $0 | – | -262,515 | -100.0% | -1.54% | – |
| FLML | Exit | FLAMEL TECHNOLOGIESsponsored adr | $0 | – | -267,747 | -100.0% | -1.56% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC | $0 | – | -352,350 | -100.0% | -2.45% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.